Histologic Grading of Urothelial Papillary Neoplasms: Impact of Combined Grading (two-numbered Grading System) on Reproducibility

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2011 Apr 13

PMID 21484429

Citations 6

Authors

Burcin Tuna

Kutsal Yorukoglu

Ender Duzcan

Sait Sen

Nalan Nese

Banu Sarsik

Aysegul Akder

Sehnaz Sayhan

Ugur Mungan

Ziya Kirkali

Affiliations

Soon will be listed here.

Abstract

The clinical management of tumor patients is often strongly influenced by the tumor grade. The presence of heterogeneity is well recognized in a variety of tumors. Overall grade is based on highest grade area identified within a tumor. Urothelial carcinoma often contains different histological grades within the same tumor. This study investigates the impact of a combined grading system on the reproducibility of papillary urothelial neoplasms. A set prepared for an earlier study consisting of ten cases of each category (papillary urothelial neoplasm of low malignant potential (PUNLMP), LGPUC, and HGPUC) was used. Agreement between pairs of pathologists was evaluated using κ statistics for the combined scoring system. Interobserver agreement was fair to substantial as reflected by κ values ranging from 0.24 to 0.74 (mean κ = 0.43). The combined scores of 2 and 3 which included PUNLMP showed the lowest degree of agreement and when this category was excluded from the analysis, interobserver agreement increased significantly (mean κ = 0.65; ranging from 0.43 to 0.92) in terms of combined scores of 4, 5, and 6. PUNLMP has been shown to be the least reproducible component of a combined scoring system even among experienced observers. Exclusion of PUNLMP from grading scheme seems to improve interobserver variability.

Citing Articles

Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors.

Guo C, Shen S, Czerniak B Bladder Cancer. 2024; 9(1):1-14.

PMID: 38994481 PMC: 11181758. DOI: 10.3233/BLC-220106.

Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.

Savchenko E, Bunimovich-Mendrazitsky S Front Med (Lausanne). 2024; 11:1388685.

PMID: 38808135 PMC: 11130437. DOI: 10.3389/fmed.2024.1388685.

Development and reliability of the histological THROMBEX-classification rule for thrombotic emboli of acute ischemic stroke patients.

Ribbat-Idel J, Stellmacher F, Jann F, Kalms N, Konig I, Ohlrich M Neurol Res Pract. 2021; 3(1):50.

PMID: 34538282 PMC: 8451083. DOI: 10.1186/s42466-021-00149-6.

First approach to distinguish between cardiac and arteriosclerotic emboli of individual stroke patients applying the histological THROMBEX-classification rule.

Roessler F, Kalms N, Jann F, Kemmling A, Ribbat-Idel J, Stellmacher F Sci Rep. 2021; 11(1):8433.

PMID: 33875717 PMC: 8055901. DOI: 10.1038/s41598-021-87584-2.

Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database.

Xu Z, Wang C, Xiang X, Li J, Huang J Med Sci Monit. 2019; 25:3041-3060.

PMID: 31020952 PMC: 6498884. DOI: 10.12659/MSM.915487.

References

Ooms E, Anderson W, Alons C, Boon M, Veldhuizen R . Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol. 1983; 14(2):140-3. DOI: 10.1016/s0046-8177(83)80242-1. View

Montironi R, Mazzucchelli R, Colanzi P, Streccioni M, Scarpelli M, Thompson D . Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network. Eur Urol. 2002; 41(4):449-57. DOI: 10.1016/s0302-2838(02)00028-3. View

Epstein J, Amin M, Reuter V, Mostofi F . The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22(12):1435-48. DOI: 10.1097/00000478-199812000-00001. View

Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K . Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003; 92(6):559-62. DOI: 10.1046/j.1464-410x.2003.04415.x. View

Samaratunga H, Makarov D, Epstein J . Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002; 60(2):315-9. DOI: 10.1016/s0090-4295(02)01705-3. View

Cheng L, NEUMANN R, Nehra A, Spotts B, Weaver A, Bostwick D . Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer. 2000; 88(7):1663-70. DOI: 10.1002/(sici)1097-0142(20000401)88:7<1663::aid-cncr21>3.0.co;2-8. View

Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S . Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch. 2003; 443(6):734-40. DOI: 10.1007/s00428-003-0905-0. View

Robertson A, BECK J, Burnett R, Howatson S, Lee F, Lessells A . Observer variability in histopathological reporting of transitional cell carcinoma and epithelial dysplasia in bladders. J Clin Pathol. 1990; 43(1):17-21. PMC: 502217. DOI: 10.1136/jcp.43.1.17. View

Shariat S, Ashfaq R, Sagalowsky A, Lotan Y . Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007; 177(2):481-7. DOI: 10.1016/j.juro.2006.09.038. View

10.

van Rhijn B, van der Kwast T, Vis A, Kirkels W, Boeve E, Jobsis A . FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004; 64(6):1911-4. DOI: 10.1158/0008-5472.can-03-2421. View

11.

Abel P, Henderson D, Bennett M, Hall R, Williams G . Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol. 1988; 62(4):339-42. DOI: 10.1111/j.1464-410x.1988.tb04361.x. View

12.

Jones T, Cheng L . Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol. 2006; 175(6):1995-2003. DOI: 10.1016/S0022-5347(06)00267-9. View

13.

Cheng L, NEUMANN R, Bostwick D . Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer. 1999; 86(10):2102-8. View

14.

Oosterhuis J, Schapers R, Janssen-Heijnen M, Pauwels R, Newling D, Ten Kate F . Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol. 2002; 55(12):900-5. PMC: 1769816. DOI: 10.1136/jcp.55.12.900. View

15.

Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A . Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer. 2002; 95(4):784-90. DOI: 10.1002/cncr.10733. View

16.

Wells W, Carney P, Eliassen M, Grove M, Tosteson A . Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. Am J Surg Pathol. 2000; 24(5):651-9. DOI: 10.1097/00000478-200005000-00003. View

17.

Murphy W, Takezawa K, Maruniak N . Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002; 168(3):968-72. DOI: 10.1016/S0022-5347(05)64553-3. View

18.

Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson S . Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999; 162(3 Pt 1):702-7. DOI: 10.1097/00005392-199909010-00019. View

19.

Bircan S, Candir O, Serel T . Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int. 2004; 73(3):201-8. DOI: 10.1159/000080828. View

20.

van Rhijn B, van Leenders G, Ooms B, Kirkels W, Zlotta A, Boeve E . The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. 2009; 57(6):1052-7. DOI: 10.1016/j.eururo.2009.09.022. View